Search
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalSynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study). … SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech.
DCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).
Linopristin
go.drugbank.com/drugs/DB19296ExperimentalThe combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections. … Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with [Virginiamycin M1].
Azilsartan mopivabil
go.drugbank.com/drugs/DB21569ExperimentalThe usage of the INN stem '-sartan' in the name indicates that Azilsartan mopivabil is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Azilsartan mopivabil is a small molecule drug.
Vilamakitug
go.drugbank.com/drugs/DB18978InvestigationalVilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic
Rintodestrant
go.drugbank.com/drugs/DB21472InvestigationalRintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer). … Rintodestrant is a small molecule drug.
Ravagalimab
go.drugbank.com/drugs/DB16676InvestigationalRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis
XmAb24306
go.drugbank.com/drugs/DB17526InvestigationalXmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.